Interleukin-2 (IL-2) after autologous stem cell transplantation (SCT) is being explored as a way of reducing relapse. To determine the immunostimulating effect of low-dose subcutaneous IL-2 following SCT, the in vitro and in vivo activity of patient peripheral blood mononuclear cells (PBMNC) was studied. A predominantly natural killer (NK) lymphocytosis was induced and sustained throughout most of the IL-2 treatment period. The in vivo primed PBMNC had enhanced lytic activity against a variety of tumor targets. The in vitro cytotoxicity of in vivo IL-2-primed PBMNC could be increased further by overnight incubation in 1000 U/ml IL-2. High-dose chemo-radiotherapy followed by autologous stem cell transplantation is considered the best salvage therapy for patients with high-risk and recurrent lymphoma. [1] [2] [3] However, the risk of relapse remains high and has been attributed in part to residual tumor in the patient and/or in the graft, as well as to the lack of any autologous graft- versus-tumor effect. [4] [5] [6] In an attempt to decrease the rate of relapse, we and others have evaluated the role of interleukin-2 (IL-2)-based immunotherapy following autologous stem cell transplantation.
versus-tumor effect. [4] [5] [6] In an attempt to decrease the rate of relapse, we and others have evaluated the role of interleukin-2 (IL-2)-based immunotherapy following autologous stem cell transplantation. [7] [8] [9] [10] The presence of IL-2-responsive effector cells during a state of minimal residual disease supports the use of immunotherapy in the early post-transplant period. 11 Concern about the severity of side-effects seen with high-dose intravenous IL-2 following stem cell transplantation (SCT) 10 prompted us to investigate the potential role of low-dose subcutaneous IL-2. 12 This regimen was designed to induce natural killer (NK) cell activation following autologous transplantation in the outpatient setting.
The clinical significance of an IL-2-induced increment in NK numbers and cytolysis in transplant recipients is not yet known. We therefore developed a severe combined immunodeficient (SCID) mouse model of human B cell lymphoma in order to evaluate whether treatment of autotransplanted patients with subcutaneous IL-2 would result in generation of peripheral blood mononuclear cells (PBMNC) that were therapeutically effective against lymphoma in vivo. Correlation of the degree of in vitro cytotoxicity with improved survival in SCID mice would validate this model as an in vivo biologic assay to predict the efficacy of immunotherapy with IL-2 following stem cell transplantation.
Materials and methods

Patients
Adult recipients of autologous bone marrow or peripheral blood stem cell transplantation for non-Hodgkin's lymphoma (non-T cell) or Hodgkin's disease or advanced breast cancer were eligible for a phase I trial of IL-2 following recovery from toxicities related to the autologous transplant procedure. 12 Preparative regimens for lymphoma and breast cancer consisted of cyclophosphamide and total body irradiation, or cyclophosphamide, thiotepa, carboplatinum and etoposide, respectively. Patients were eligible to start IL-2 therapy between 30 and 180 days post-transplant and after achieving independence from transfusion support and growth factors with a platelet count Ͼ80 × 10 9 /l, hemoglobin Ͼ9 g/dl and absolute neutrophil count (ANC) Ͼ1 × 10 9 /l. Patients needed to have adequate organ function (creatinine Ͻ1.5 mg/dl, liver function tests Ͻ2 times normal, pulmonary function tests Ͼ60% of predicted, and no evidence of cardiac disease). All patients were free of active infection, receiving no i.v. antibiotics or parenteral nutrition. Patients with residual tumor requiring post-transplant radiation had completed therapy and no patients were receiving immunosuppressive medication (steroids). When eligible for IL-2 therapy, patients exercised voluntary informed consent according to guidelines approved by the Committee on the Use of Human Subjects in Research at the University of Minnesota under a protocol reviewed and approved by the US Food and Drug Administration. Patients received instructions to self-administer IL-2 subcutaneously for 84 daily doses (12 weeks).
Lymphocyte collections from three patients receiving subcutaneous IL-2 were used for these studies, two with a diagnosis of non-Hodgkin's lymphoma and one with a diagnosis of breast cancer. All patients received IL-2 after full hematologic recovery from autologous transplantation without transfusions at a dose determined to result in significant increases in circulating NK cells (two patients received 0.25-0.5 × 10 6 /m 2 /day Amgen IL-2 (Thousand Oaks, CA, USA) and one received 1.75 × 10 6 /m 2 /day Chiron IL-2 (Emeryville, CA, USA). 12 Lymphapheresis was performed on days 35-42 after initiating IL-2 therapy based on the maximal, sustained increase in NK cells observed with the IL-2 doses administered in previous patient cohorts. 12 Laboratory assessment of immune activation PBMNC were obtained from heparinized blood by FicollHypaque as described. 13 Large scale lymphocyte activation experiments were performed after informed consent by continuous flow lymphapheresis of PBMNC from patients receiving subcutaneous IL-2 with a Fenwal CS3000 blood cell separator (Baxter, Deerfield, IL, USA) as described. 14 Cells were cultured in AIM-V serum-free medium (GIBCO BRL, Grand Island, NY, USA) supplemented with (or without) 1000 U/ml IL-2 in polyolefin gas permeable bags (Lifecell Tissue Culture Flask, Fenwal-Baxter).
Fresh PBMNC or overnight (14-18 h) IL-2-activated PBMNC (1000 U/ml recombinant IL-2) were tested for cytotoxicity against the NK-sensitive cell line K562 (American Tissue Type Collection, Rockville, MD, USA), the NK-resistant B cell lymphoma line Raji (ATCC) and the SU-DHL-4 B lymphoma 15 (kindly provided by Dr Ronald Levy, Stanford University) in 4-h 51 Cr release assays. In other experiments the effector function of mouse splenocytes was assessed using 51 Cr release assays as described previously. 16 Cell surface antigens were determined by direct staining of cells with monoclonal antibodies at 0.15 mg/2 × 10 5 cells (Becton Dickinson, Mountain View, CA, USA). 13 
SCID mouse experiments
Six-to 10-week-old female C.B-17 scid/scid mice (NIH, Frederick, MD, USA) were used for the experiments. The animals were housed in a specific pathogen-free facility in microisolator cages with autoclaved food, water and bedding. Mice were cared for according to the University of Minnesota Research Animal Resources guidelines. To further suppress immune function and ensure tumor growth, all mice were given 200 cGy of total body irradiation ( 137 Cs; 57.5 cGy/min) on day −1. SU-DHL-4 lymphoma cells (2 × 10 6 ) were given i.v. via tail vein injection on day 0.
On day +1, some groups of lymphoma-bearing mice received 20 × 10 6 PBMNC collected from patients treated with subcutaneous IL-2 following autologous transplantation. Before i.v. infusion into mice these patients' cells were cultured in AIM-V serum-free medium (GIBCO) with or without 1000 U/ml IL-2. Cells that were cultured in IL-2 were washed before they were infused into mice. Control mice received either saline or PBMNC from healthy volunteers. Certain groups of mice received IL-2 25 000 U/day i.p. between days +1 and +7.
Statistical analysis
The Kaplan-Meier product-limit method was used to assess the survival of mice. 17 The log-rank statistic was used to test differences between groups.
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Results
Lytic function of PBMNC from patients receiving IL-2 following autologous stem cell transplantation
An increase in absolute numbers of natural killer cells was induced by subcutaneous IL-2 following autologous SCT from a median of 110 per l prior to initiating IL-2 to 1245 per l at the time of lymphapheresis. The NK cell lymphocytosis was sustained throughout most of the IL-2 treatment period and accompanied by eosinophilia (median absolute count, 1000 per l). From the actual lymphapheresis product (day 35-42 of IL-2 treatment), a median of 62% (59-83%) of mononuclear cells were CD56 +bright /CD3 − natural killer cells of which approximately 50-60% also coexpressed CD8 and CD16. Of the median 29% (14-34%) T cells in the lymphapheresis product, 44% were CD8 + and 56% were CD4 + . Lytic function of PBMNC harvested from transplanted patients receiving IL-2 was evaluated in cytotoxicity assays using the NK-sensitive target, K562, and the B cell lymphoma targets, SU-DHL-4 and Raji. After 35-42 days of subcutaneous IL-2, patients' fresh PBMNC had substantial cytotoxicity against K562 and SU-DHL-4 but less against Raji targets (Figure 1 ). We then examined whether cytotoxicity of in vivo primed PBMNC could be increased by overnight incubation with 1000 U/ml IL-2. Ex vivo activation 
The SCID SU-DHL-4 human lymphoma model
In an attempt to develop a suitable in vivo system for evaluating the efficacy of cellular therapy for lymphoma, we examined the SU-DHL-4 xenotransplantation model. Groups of irradiated C.B-17 mice were injected i.v. with increasing numbers of SU-DHL-4 cells to determine whether mortality would correlate with the size of the tumor inoculum. The time to death was dependent on the number of human lymphoma cells injected into mice. However, significant differences in survival were only apparent between groups receiving at least four-to five-fold more tumor cells ( In every experiment, autopsies were performed in two to three mice from each group to confirm that deaths were in fact due to metastatic lymphoma. All mice died as a result of tumor progression and were found to have marked lymphadenopathy and hepatosplenomegaly. Flow cytometric analysis revealed Ͼ10% CD19 + lymphoma cells in the spleen and Ͼ25% in the bone marrow. The majority of mice developed hind limb paralysis 1-5 days prior to death. Histologic sections showed evidence of lymphomatous infiltration of brains and/or spinal columns.
IL-2 prolongs survival of SCID mice bearing human lymphoma by activation of murine NK cells
Although SCID mice are deficient in functional T and B lymphocytes, they have normal or enhanced NK activity. We therefore evaluated whether IL-2 would affect the survival of lymphoma-bearing SCID mice. Infusion of 2 × 10 resulted in death of untreated animals at a median time (MST) of 33 days. Treatment with human recombinant IL-2 (25 000 U i.p. for 7 days), beginning 1 day following tumor inoculation, significantly prolonged survival (MST = 63.5 days, P Ͻ 0.002). The improved survival following IL-2 treatment was in part due to enhancement of SCID mouse NK function since repeated injections of antiasialo GM1, which depleted murine NK cells in vivo, significantly inhibited the effect of IL-2 (data not shown).
To confirm that IL-2 does in fact enhance cytolytic activity of SCID mouse splenocytes against human lymphoma, we cultured C.B-17 splenocytes for 5 days in the presence of IL-2 (1000 U/ml). IL-2 stimulation resulted in the generation of murine effector cells with substantial cytotoxicity activity against SU-DHL-4 while unstimulated fresh splenocytes were not cytolytic against the human B cell lymphoma line (Figure 3) .
Activated PBMNC from patients receiving subcutaneous interleukin-2 following autologous stem cell transplantation prolong survival of SCID mice bearing human lymphoma
We next tested whether the SCID-human lymphoma model can be used to assess the immunotherapeutic potential of in vivo activated PBMNC harvested from patients receiving IL-2 post-SCT. In these experiments, PBMNC were given to mice without exogenous IL-2 since human IL-2 enhances mouse NK activity therefore potentially complicating our evaluation of the direct anti-lymphoma effect of adoptively transferred human PBMNC.
PBMNC obtained by apheresis from autografted patients that had received post-transplant subcutaneous IL-2 for 35-42 days were infused i.v. into SU-DHL-4 lymphoma-bearing C.B-17 SCID mice. While control mice died of disseminated lymphoma at a median of 35.2 days, murine recipi- ents of in vivo activated human PBMNC cells (from patients receiving IL-2) survived significantly longer (MST 58.2 days; P Ͻ 0.001, Figure 4 ). Since our in vitro cytolytic data indicated that additional overnight stimulation of in vivo primed PBMNC with IL-2 (1000 U/ml) enhanced their cytolytic activity, we directly compared the in vivo potency of the in vivo primed PBMNC cultured overnight in the presence or absence of IL-2. Although IL-2-primed PBMNC that were cultured for 14-18 h in IL-2 also improved outcome of mice over saline-treated controls (MST 58 days; P Ͻ 0.001), they did not offer a survival advantage over primed PBMNC that were incubated in the absence of IL-2 (P = NS, Figure 4 ). Our tumor dose-response studies indicated that a five-fold reduction in tumor inoculum resulted in a significant increase in survival (Figure 2) . Therefore, this in vivo model was not sufficiently sensitive to distinguish a threefold difference in in vitro cytolytic activity (against SU-DHL-4) observed using in vivo primed PBMNC cultured overnight in the presence or absence of IL-2 ( Figure 1) .
It was not possible to harvest adequate PBMNC from autotransplant recipients pre-IL-2 to use as controls in the SCID mouse experiments. However, we did find that the in vitro cytolytic activity of PBMNC from patients (before IL-2 therapy) was comparable to that of healthy donor PBMNC (data not shown). Therefore, in additional experiments we examined whether control human PBMNC would also prolong survival of tumor-bearing mice. This was particularly important to determine since SU-DHL-4 is somewhat sensitive to in vitro lysis by fresh PBMNC at high effector to target ratios ( Figure 5 ). Infusion of fresh PBMNC from an untreated healthy donor had little impact on survival ( Figure 6 ) while PBMNC from an auto stem cell transplant recipient treated with subcutaneous IL-2 significantly improved outcome (P Ͻ 0.007). This suggests that the anti-lymphoma effect of patient PBMNC was . PBMNC from the same patient and healthy donor used in Figure 5 were used in this experiment. dependent on prior in vivo activation by therapeutic IL-2. These findings were consistent with our in vitro data demonstrating that PBMNC from the same patient treated with IL-2 post-transplantation was at least 30-fold more potent in lysing SU-DHL-4 compared to PBMNC from the untreated healthy control ( Figure 5 ).
Discussion
We have recently reported results of a phase I trial of low dose subcutaneous IL-2 given to patients following autologous stem cell transplantation in an outpatient setting. 12 Subcutaneous IL-2 was easy to administer and was associated with minimal toxicity. Immune activation was evident as early as 14 days following initiation of therapy, with NK lymphocytosis and augmentation of cell-mediated lysis.
PBMNC obtained by apheresis from patients receiving low-dose IL-2 for 35-42 days, significantly prolonged survival of mice bearing the human B cell lymphoma SU-DHL-4. The survival of mice treated with in vivo activated PBMNC cells was comparable to mice receiving about 20-fold less SU-DHL-4 cells (equivalent to 1.3 log cell kill). Our data show that activated, but not control or unactivated lymphoid cells, can extend survival in B cell lymphoma bearing mice. The in vivo effect of human PBMNC on survival of tumor bearing mice correlated well with their in vitro cytolytic activity as assessed by 51 Cr release assays. To our knowledge this study is the first to describe the in vivo efficacy in a SCID model of human effector cells obtained from patients receiving immunotherapy following stem cell transplantation. Whether this model can be used reliably to predict treatment outcome of patients receiving IL-2 remains to be determined. SCID mice, which lack functional T and B lymphocytes, have been used to develop xenotransplantation tumor models. Human tumors growing in immunodeficient mice have allowed the in vivo evaluation of new therapeutic approaches in tumor immunology and have proved useful in evaluating the efficacy of cytokines, monoclonal antibodies and immunotoxins. [19] [20] [21] [22] [23] Human B cell lymphoma lines have been successfully transplanted into SCID mice. 24, 25 The SU-DHL-4 SCID model was first described by Schmidt-Wolf et al 25 who tested the efficacy of ex vivo generated 'cytokine induced killer cells' in purging bone marrow contaminated with lymphoma cells. They demonstrated that mice receiving SU-DHL-4 contaminated bone marrow that was treated ex vivo with human PBMNC, cultured for 20 days in the presence of anti-CD3, IL-2, IFN-␥ and IL-1, had prolonged survival when compared to SCID mice receiving unpurged bone marrow.
We recognize the limitations in SCID-human tumor models since interactions between adhesion/homing molecules and their xenogeneic receptors may hamper effective trafficking of human lymphoid cells to distal sites of tumor implantation. Perhaps a more ideal model would be to inject the patient's autologous tumor into SCID mice, establish lymphoma growth and then treat tumor-bearing mice with autologous PBMNC. However, multiple attempts at injecting fresh patient lymphoma cells intravenously and intraperitoneally into irradiated SCID mice did not result in tumor growth. Others have shown that pretreatment of SCID mice with anti-asialo G M1 and total body irradiation improves engraftment of human cells. 26 In our experience this conditioning also failed to promote growth of freshly explanted human tumors in SCID mice. Despite these limitations our model does provide an in vivo system where it is possible test the efficacy of human NK cells. The in vivo model data also support the viability and homing capacity of these cells to be of potential clinical value.
The in vivo effect of adoptively transferred activated PBMNC was likely due to direct cytotoxicity by human NK cells. Several observations suggest that human NK cells do not produce IL-2 which could indirectly stimulate murine NK cells. We have found that human activated NK cells, unlike T cells, do not survive or proliferate without exogenous IL-2 suggesting that they do not produce this cytokine. 27 Others have also demonstrated that NK cells are unable to produce IL-2 or are very poor producers. In one study comparing T and NK cell clones, the majority of the T cell clones produced high levels of IL-2, whereas all the NK clones produced very low or undetectable IL-2.
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The HLA-type of the patients was not known and therefore the PBMCs were likely HLA-mismatched with the SU-DHL-4 lymphoma. Although NK clones have the ability to recognize class I MHC which down-regulates subsequent target lysis, the physiologic relevance of using polyclonal NK cells is uncertain. Since the majority of the cytolytic activity in the IL-2-stimulated PBMNC was due to MHC nonrestricted killing mediated by activated NK cells, histoincompatibility had a minor effect in this system. PBMNC from additional patients studied as part of this trial had similar cytolytic activity against these targets despite different HLA types. 12 In summary, we have established a human B cell lymphoma model by injecting SU-DHL-4 lymphoma cells intravenously into irradiated C.B-17 SCID mice. This model system was used to evaluate the in vivo antitumor effect of human PBMNC which were activated by low-dose subcutaneous IL-2 given to patients following autologous transplantation. The in vivo effect of human lymphoid effectors correlated well with their in vitro cytolytic activity indicating that the SCID SU-DHL-4 lymphoma model can be utilized reliably to test the efficacy of cellular therapy in vivo. This model may be used for testing alternative schedules, doses of cytokines and cell types for post-transplant immunotherapy.
